No Data
No Data
No Data
No Data
No Data
Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial
Avecho Biotechnology (ASX:AVE) has begun patient recruitment for the Phase III clinical trial of its anti-insomnia medication, the company said in a Tuesday filing with the Australian Securities Excha
MT NewswiresMar 25 18:37 ET
Avecho to Push Forward With Phase III Trial of Anti-Insomnia Drug
Avecho Biotechnology (ASX:AVE) said the Australian Therapeutic Goods Administration (TGA) has "not recommended any changes" to the design and submission strategy of the firm's proposed Phase III clini
MT NewswiresMar 14 07:41 ET
Avecho Biotechnology Secures Ethics Clearance for Phase Three Insomnia Trial
Avecho Biotechnology (ASX:AVE) secured ethics approval to advance its phase three insomnia trial, according to a filing with the Australian Securities Exchange on Thursday. The study aims to investiga
MT NewswiresMar 7 01:11 ET
Stocks of the Hour: Dotz Nano, Immuron, Avecho Biotechnology
To register for Friday's webinar click here.Dotz Nano (ASX:DTZ, OTC:DTZNY), a leading developer of innovative climate and industrial nanotechnologies, today announced the completion of a bench-scale d
sharecafeMar 6 19:43 ET
Avecho Biotechnology (ASX:AVE) Passes "Crucial" Two-year Stability Milestone for CBD Capsule
The Market HeraldJun 22, 2023 01:33 ET
Avecho Biotechnology (ASX:AVE) Completes the Development of Proprietary TPM Cannabinoid Gummies
The Market HeraldJun 6, 2023 23:55 ET
No Data
No Data